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AIMS. Populations of African ancestry suffer high rates of type 2 diabetes (T2D) compared to 26 
Caucasians. Phenotypic differences in pre-diabetic populations, particularly marked 27 
hyperinsulinaemia, suggest ethnic distinctions in T2D pathophysiology. We tested the 28 
hypothesis that men of Black (West) African (BAM) ethnicity with early T2D would have 29 
greater insulin secretory deficits compared to White Europeans (WEM), following the pre-30 
diabetic hypersecretion. 31 
METHODS. In 19 BAM and 15 WEM, matched for age, BMI and duration diabetes, we 32 
assessed and modelled insulin secretory responses to hyperglycaemia stimulated intravenously 33 
(hyperglycaemic clamp) and orally (meal tolerance test).  34 
RESULTS. With comparable post-challenge glucose responses, BAM exhibited lower second 35 
phase c-peptide response to intravenous (BAM 70.6 vs WEM 115.1nmol/l min-1 (ratio of 36 
geometric mean 0.55, 95%CI 0.37,0.83) p=0.006) and oral (BAM 65.4 vs WEM 88.5nmol/l 37 
min-1 (mean difference -23.2 (95%CI -40.0,-6.3) p=0.009) glucose. BAM peripheral insulin 38 
response to oral glucose was preserved (BAM 47.4 vs WEM 59.4nmol/l min-1 (ratio of 39 
geometric mean 0.89 (95%CI 0.59,1.35) p=0.566), with relative reductions in insulin clearance 40 
(BAM 506.2 vs WEM 630.1 mL/m2 BSA min-1 (mean difference -123.9 (95%CI -270.5, 22.6) 41 
p=0.095), associated with enhanced incretin responses (GIP iAUC: BAM 46.8 vs WEM 42 
33.9µg/l min-1 (mean difference 12.9 (95%CI 2.1,23.7) p=0.021). 43 
CONCLUSIONS. In early T2D, BAM exhibit significantly lower insulin secretory responses 44 
to intravenous and oral stimulation compared to WEM. Lower insulin clearance, potentially 45 
driven by increased incretin responses, may act to preserve peripheral insulin concentrations. 46 
Tailoring early management strategies to reflect distinct ethnic-specific pathophysiology may 47 
improve outcomes for this high risk population.  48 
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Populations of African ancestry are disproportionately affected by type 2 diabetes (T2D) (1); 61 
it develops at younger age (2) and lower body mass (3) than amongst Caucasians.  62 
The main pathophysiological processes of insulin secretory failure and insulin resistance that 63 
underlie T2D are well documented (4) but differences in the pathogenesis based on ethnicity 64 
are increasingly recognised. There is a growing literature examining metabolism in non-65 
diabetic Black populations, with studies in non-diabetic African-American children and 66 
adolescents describing marked hyperinsulinaemia compared to other ethnicities (5-11) and 67 
extensive reports that Black populations, both indigenous (12) and diasporic (13-19), exhibit a 68 
hyperinsulinaemic response to glucose. Conventionally hyperinsulinaemia is understood to 69 
occur in response to heightening insulin resistance, however this does not fully explain the 70 
response in Black populations (6, 9, 11). Studies in children measuring c-peptide have 71 
described a combination of increased insulin secretion and reduced hepatic insulin clearance 72 
(7, 9). Studies in healthy and prediabetic adults have shown lower rates of insulin clearance 73 
(13, 15, 19) but heterogeneity in the populations has made independence from insulin resistance 74 
and body weight/composition differences difficult to ascertain. If intensified hyperinsulinaemia 75 
represents greater insulin secretion, it may predispose to earlier beta-cell exhaustion in the 76 
development of T2D. To date no studies have undertaken comparisons of beta-cell function in 77 
Black African and White European populations with recent-onset T2D. As this may be the time 78 
people first present to health services, this is an important phase to understand. 79 
The measurement of insulin secretory capacity is complex. Techniques based on the 80 
measurement of circulating insulin concentrations only partially reflect insulin secretion and 81 
fail to account for hepatic insulin clearance. Measurement of c-peptide overcomes this and 82 
reflects more precisely true pancreatic insulin secretion. The intravenous glucose tolerance test 83 
is the most commonly used method but it is often restricted to assessing only first phase 84 
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secretion; the hyperglycaemic clamp is a more rigorous method that distinguishes first and 85 
second phase secretion however it does not account for the role of incretin hormones, which 86 
can be assessed by a meal tolerance test. 87 
The purpose of this study was to assess comprehensively insulin secretory function, in response 88 
to both intravenous and oral stimulation, to explore the hypothesis that men of Black (West) 89 
African (BAM) ethnicity will have significantly greater insulin secretory deficits compared to 90 
White European men (WEM) by the time they manifest T2D.  91 
  92 
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MATERIALS & METHODS 93 
The study was conducted at the Clinical Research Facility (CRF), King’s College London, UK 94 
and approved by the London Bridge National Research Ethics Committee (12/LO/1859); all 95 
participants provided informed consent. Recruitment and data collection took place April 2013-96 
January 2015. 97 
Participants 98 
Men of Black West African or White European ethnicity (self-declared, confirmed by 99 
grandparental birthplace), aged 18-65 years, BMI 25-35 kg/m2, with a documented diagnosis 100 
of T2D within 5 years, treated with lifestyle advice ± metformin, and HbA1c ≤63·9 mmol/mol 101 
(<8%) were recruited from South London General Practices taking part in an early detection 102 
T2D screening programme (20). Participants were deemed ineligible if: treated with other 103 
diabetes medications, chronic oral steroids, beta-blockers; serum creatinine >150 mmol/l; 104 
serum alanine transaminase level >2.5-fold above the upper limit of the reference range; 105 
positive auto-antibodies for anti-insulin, anti-GAD or anti-A2; sickle cell disease (trait 106 
permitted); or medications believed to affect the outcome measures. Participants completed a 107 
medical screening before study entry. BAM were matched with WEM for age (± 5 years) and 108 
BMI (± 3 kg/m2). 109 
Study design 110 
Assessment visits were completed in random order and separated by a minimum of 7 days. For 111 
each assessment participants arrived  having refrained from eating or drinking anything other 112 
than water from 10pm the night prior. Participants were instructed to refrain from strenuous 113 
exercise and physical activity in the preceding 48 hours and from alcohol in the preceding 24 114 
hours , and to consume a standardised diet the day prior (~50% of calories from carbohydrate, 115 
evenly spread throughout the day, with no more than 30% of daily carbohydrate consumed in 116 
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the evening meal). Participants on metformin were instructed to cease taking it for 7 days prior 117 
to the visit. 118 
Hyperglycemic clamp assessment of first and second phase insulin secretory function. A two-119 
hour hyperglycaemic clamp was conducted (21). Participants were weighed in light clothing 120 
and their body surface area (BSA) calculated (22). An antecubital fossa vein was cannulated 121 
for administration of intravenous glucose; a second cannula was inserted retrogradely into the 122 
dorsum of the hand, and placed in a warming unit, to achieve arterialised venous blood samples. 123 
Three fasting samples (-20, -10 and 0 minutes) were collected before starting the glucose 124 
infusion (20% glucose) at time 0 minutes; a priming regimen, based on BSA (23), was used 125 
for the first 15 minutes to increase rapidly the plasma glucose to 6.9 mmol/l above fasting. The 126 
glucose infusion rate was then adjusted to maintain plasma glucose at 6.9 mmol/l above fasting 127 
for a further 105 minutes. Blood sampling occurred every 2 minutes for the first 10 minutes 128 
and every 5 minutes thereafter to inform adjustment of the glucose infusion rate for ‘clamping’ 129 
the plasma glucose. Blood samples were drawn at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, 90, 130 
105 and 120 minutes for the assessment of plasma glucose, and serum insulin and c-peptide.  131 
Mixed meal tolerance test assessment of insulin and incretin secretion. A three-hour meal 132 
tolerance test was conducted using a liquid milkshake (Ensure Plus, Abbott Nutrition, UK), 133 
providing 6 kcals/kg body weight. An antecubital fossa vein was cannulated for blood 134 
sampling. Following the collection of fasting samples at time -10 and 0 minutes the participants 135 
consumed the drink within 5 minutes. Blood was collected at 10, 20, 30, 40, 50, 60, 75, 90, 136 
120, 150 and 180 minutes for the assessment of glucose, non-esterified fatty acids (NEFA), 137 
insulin and c-peptide, and for GLP-1 and GIP at 30, 60 and 120 minutes. 138 
Magnetic resonance imaging assessment of visceral fat deposition. Visceral fat and skeletal 139 
muscle mass were assessed using MRI, in a 1.5T Siemens scanner. Participants lay supine and 140 
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a single T1-weighted axial image, of 3mm thickness, was acquired at the L4-L5 region of the 141 
abdomen and the thighs (20cm below the neck of the femur), using a two-point variant Dixon 142 
imaging protocol. The area of visceral fat and volume of skeletal muscle was quantified using 143 
Osirix image processing software, version 6.0.2 (Pixemo, Switzerland). 144 
Analyses of samples and calculations. We measured plasma glucose by automated glucose 145 
analyser (Yellow Spring Instruments, Ohio, USA); serum insulin by immunoassay using 146 
chemiluminescent technology (ADVIA Centaur System, Siemens Healthcare Ltd. Camberly, 147 
UK); serum c-peptide by radioimmunoassay (Millipore Ltd, Hertfordshire, UK); plasma NEFA 148 
by enzymatic colorimetric assay (Wako Diagnostics, Richmond, VA, USA) on an automated 149 
clinical chemistry analyser (ILab 650, Instrument Laboratories, Holliston, MA, USA); and 150 
GLP-1 and GIP (total) by fluorescent ELISA methods (EGLP-35K and EZHGIP-54K, Merck 151 
Millipore, UK). 152 
The area under the curve (AUC) and incremental AUC (iAUC) were calculated, using the 153 
trapezoidal rule, for insulin, c-peptide, glucose, NEFA, GLP-1 and GIP. To calculate an index 154 
of first and second phase insulin secretion in the hyperglycaemic clamp we measured the iAUC 155 
for c-peptide over 0-10 minutes for first phase, and 10-120 minutes for second phase, in 156 
analogy to DeFronzo et al. (21).  157 
Model-based measurement of beta-cell function: the glucose, insulin and c-peptide curves 158 
during the hyperglycaemic clamp and meal tolerance test were modelled using methods 159 
previously described (24-26) (SAAM-II 1.2 software; SAAM Institute, Seattle, WA). The main 160 
outputs of the hyperglycaemic clamp model are: glucose sensitivity of first-phase secretion 161 
(1), expressed as the amount of insulin secreted in response to a rate of increase in glucose of 162 
1 mmol/l between time 0 and 1 min of the study, in (𝑝𝑚𝑜𝑙 ∙ 𝑚−2 𝐵𝑆𝐴) (𝑚𝑚𝑜𝑙 ∙ 𝑙−1 ∙ 𝑚𝑖𝑛−1)⁄ ; 163 
glucose sensitivity of second-phase secretion (2), expressed as the steady state insulin 164 
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secretion rate in response to a step increase in glucose of 1 mmol/l above baseline, in 165 
(𝑝𝑚𝑜𝑙 ∙ 𝑚𝑖𝑛−1 ∙ 𝑚−2 𝐵𝑆𝐴) (𝑚𝑚𝑜𝑙 ∙ 𝑙−1)⁄ . Modelling of the glucose and c-peptide curves of 166 
the meal test enables an estimation of the equivalent of first phase insulin secretion (1), 167 
whereas second phase insulin secretion is assessed and presented through the stimulus response 168 
curve of the insulin secretion rates at 4, 5.5, 8, 11 and 15 mmol/l of glucose. The parameter 2, 169 
as defined above is the slope of the rising branch of the curve relating plasma glucose 170 
concentration to insulin secretion rate.  171 
In both the hyperglycaemic clamp and meal test, average insulin clearance was computed 172 
according to the following formula (derivation and correct interpretation are presented in 173 
Supplementary Material):  174 
𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒𝐼𝑛𝑠 =  
𝐴𝑈𝐶𝐼𝑆𝑅
𝐴𝑈𝐶1 + (𝐼𝐹𝑖𝑛𝑎𝑙  −  𝐼𝐵𝑎𝑠𝑎𝑙) ∙  𝑀𝑅𝑇𝐼𝑛𝑠
 175 
in which 𝐴𝑈𝐶𝐼𝑆𝑅 is the area under the curve of insulin secretion rate, 𝐴𝑈𝐶𝐼 is the area under 176 
the curve of insulin concentration,  𝐼𝐹𝑖𝑛𝑎𝑙 is insulin concentration at the end of the study, 𝐼𝐵𝑎𝑠𝑎𝑙 177 
is insulin concentration at the beginning of the study, and 𝑀𝑅𝑇𝐼𝑛𝑠 is the mean residence time 178 
of insulin, which was assumed to be 27 minutes as reported in (27). 179 
The reconstructions of beta cell function during the hyperglycaemic clamp and the meal 180 
tolerance test were combined to enable modelling of the effect of incretins on insulin secretion: 181 
the ‘meal effect’. This was done by taking the beta-cell reconstructed from the hyperglycaemic 182 
clamp and challenging it, in an in silico experiment, with the plasma glucose curve of the meal 183 
test, thus computing the time course and the total amount of insulin secretion rate; this is the in 184 
silico equivalent of infusing in vivo intravenous glucose to mimic the glucose curve seen during 185 
the meal tolerance test. The effect of the meal on beta-cell insulin secretion can be measured 186 
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by comparing the total insulin secretion of the meal in vivo with that of the in silico simulation 187 
of intravenous glucose infusion to mimic the glucose curve elicited by the meal test, i.e.: 188 
𝑀𝑒𝑎𝑙 𝑒𝑓𝑓𝑒𝑐𝑡 =  
𝐴𝑈𝐶 𝐼𝑆𝑅𝑀𝑒𝑎𝑙−𝐴𝑈𝐶 𝐼𝑆𝑅𝐼𝑛𝑡𝑟𝑎𝑣𝑒𝑛𝑜𝑢𝑠
𝐴𝑈𝐶 𝐼𝑆𝑅𝑀𝑒𝑎𝑙
  189 
Further details of the computation of the ‘meal effect’ are provided in Supplementary Material. 190 
Statistics 191 
All datasets were tested for normality (Shapiro-Wilks test) and non-normally distributed 192 
variables were transformed (log 10) for analysis. Normally-distributed data are expressed as 193 
mean ± standard deviation, and log-normal data were back transformed to give geometric mean 194 
and 95% CI for the ratio of the geometric mean. Differences between ethnic groups were 195 
determined by independent samples t-test using the raw data where they were normally 196 
distributed or logarithmic-transformed data where not. p ≤0.05 was considered statistically 197 
significant. Note that for the data analysed on the natural scale, the null value is 0 and so where 198 
p<0.05, the 95% CI will exclude 0 but for the data analysed on the log scale and back-199 
transformed to give the ratio of geometric means, the null value is 1 and so where p<0.05, the 200 
95% CI will exclude 1. The relationship between average insulin clearance and average insulin 201 
concentration was analysed by linear and nonlinear regression analysis, as described in 202 
Supplementary Material. Analyses were performed using SPSS software, version 24 (IBM 203 
Analytics, NY).  204 




Thirty-four participants, 19 BAM and 15 WEM, were studied, mean age 54.7 9 (SD 7.4) years, 207 
BMI 29.7 (SD 2.7) kg/m2. The participants had been diagnosed with diabetes for 2.9 (SD 1.1) 208 
years, mean HbA1c was 49.3 (SD 7.6) mmol/mol; 65% of participants were treated with 209 
metformin, the remainder with lifestyle management alone. By design, there were no 210 
significant ethnic differences in age, BMI, duration of diabetes, HbA1c, or management (Table 211 
1). Mean visceral fat was significantly lower, and skeletal muscle area significantly higher in 212 
BAM (Table 1). The BAM were first-generation West African migrants (born in Nigeria, n=11; 213 
Ghana, n=5; Sierra Leone, n=2, Ivory Coast, n=1).  214 
Beta-cell insulin secretory function 215 
In the hyperglycaemic clamp there were no ethnic differences in mean fasting (Table 2) or 216 
‘clamped’ glucose (BAM 14.4 ± 1.28 vs WEM 14.8 ± 1.68 mmol/l, p=0.45). Fasting c-peptide 217 
was lower in BAM (Table 2). There were no significant ethnic differences in first phase c-218 
peptide or insulin iAUC. Second phase c-peptide secretion (iAUC) was significantly lower in 219 
BAM, with a trend for 2nd phase insulin iAUC that did not achieve statistical significance 220 
(Figure 1, Table 2). The modelled glucose sensitivity of the beta cell (1 and 2) showed 221 
similar trends.   222 
During the meal tolerance test the two ethnic groups exhibited the same glucose response, 223 
however, mean c-peptide iAUC was significantly lower in BAM. The meal insulin iAUC was 224 
not significantly different between ethnic groups (Table 3, Figure 2). The modelled data from 225 
the meal tolerance test showed no significant ethnic differences in first-phase insulin secretory 226 
function (Table 3) but second-phase secretory function was lower in BAM (p=0·01). The 227 
insulin secretion rate was lower amongst BAM at 4 (p=0·019) and 5·5 mmol/l (p=0·02). This 228 
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difference was lost at higher glucose concentrations of 8 mmol/l (p=0·112), 11 (p=0·199) and 229 
15 mmol/l (p=0·247) (Figure 3). 230 
Insulin clearance 231 
There were no ethnic differences in average insulin clearance during the intravenous challenge 232 
(hyperglycaemic clamp; Table 2). In response to oral glucose the average clearance appeared 233 
lower in BAM but this difference was not statistically significant (Table 3). However, when 234 
average clearance was plotted against average insulin concentration of each test a hyperbolic 235 
relationship was apparent (Supplementary Material, Figure S8), with a clear, significant 236 
difference between the groups, implying that in BAM average insulin clearance was lower at 237 
any average insulin concentration achieved during meal/clamp tests (Figure 4).  238 
Incretin responses 239 
Mean secretion of GIP was significantly higher in BAM in response to the meal challenge 240 
(Table 3). There were no ethnic differences in GLP-1 secretion, or in the “meal effect”, the 241 
modelled effect of the mixed meal, including incretin hormones, on insulin secretion (Table 3).  242 
 243 




This study demonstrates differences in the metabolic processes involved in glucose 246 
dysregulation in men of Black African ethnicity with early T2D compared to White Europeans. 247 
Our participants had both very short duration of diagnosed disease and good metabolic control 248 
on minimal therapy (lifestyle +/- metformin only) and thus our data extend into early diabetes 249 
existing data from healthy and pre-diabetic populations. Those studies report marked 250 
hyperinsulinaemia amongst people of African ancestry (13, 15, 16); we provide novel data to 251 
show that in early T2D there is reduced insulin secretory function in response to both 252 
intravenous and oral stimuli in BAM. Whilst the insulin iAUC in the hyperglycaemic clamp 253 
was reduced in BAM, there were no differences in insulin when the meal was used to invoke 254 
hyperglycaemia via the gut. Importantly this demonstrates that the reduced hepatic insulin 255 
clearance, which has been reported in studies of healthy and prediabetic populations of African 256 
ancestry, is maintained through to early T2D and may act to maintain peripheral insulin levels, 257 
but may occur only in response to oral stimuli. Furthermore BAM exhibited significantly 258 
greater GIP responses, which may have contributed to lower average insulin clearance rates, 259 
and may have important clinical implications.  260 
Our study provides the most comprehensive assessment of the impact of Black ethnicity on 261 
beta-cell function to date. We used the intravenous glucose challenge of the hyperglycaemic 262 
clamp to distinguish first and second phase secretion, whilst the meal tolerance test assessed 263 
the physiological response of the beta-cells to nutrients, and incretin effects. In our study we 264 
have demonstrated significantly lower fasting c-peptide concentrations amongst BAM, 265 
compared to WEM of similar duration of diagnosed diabetes indicating significantly greater 266 
reduction in basal insulin secretion, although circulating insulin concentrations were not 267 
different. We also found reduced second phase insulin and c-peptide response to intravenously 268 
stimulated hyperglycaemia amongst BAM. Previous studies assessing insulin secretion in non-269 
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diabetic populations, have provided inconsistent findings (7, 10, 11); reporting higher first and 270 
second phase secretion (8), or the difference occurring only in the first (6) or second phase (5). 271 
In the aetiology of T2D, impairments in both the first and second phase insulin responses have 272 
been recognised (28, 29). The second phase response, which can only be triggered and 273 
sustained by glucose and fuel secretagogues, is quantitatively very important in the 274 
maintenance of glucose homeostasis, given that it can be sustained in response to prolonged 275 
hyperglycaemia (30). Our modelling methods enabled us to investigate the impact of ethnicity 276 
on glucose dose effects on insulin secretion, which has not previously been examined amongst 277 
populations of African ancestry. Interestingly ethnic differences in second phase insulin 278 
secretion rates at lower glucose levels were lost at higher glucose concentrations (over 8 279 
mmol/l). Since both basal and glucose tolerance are similar in the two groups, this result 280 
suggests that in the post-absorptive state insulin secretion plays a different adaptive role in the 281 
two groups.  282 
We are not aware of other studies comparing beta-cell function between BAM and WEM with 283 
T2D using the hyperglycaemic clamp. The majority of ethnic comparisons have focused on 284 
healthy or individuals at increased risk of T2D, and have predominantly used the intravenous 285 
glucose tolerance test (IVGTT) to measure the ‘acute insulin response’ (AIR), which is 286 
comparable to the first phase response of the hyperglycaemic clamp, but often only insulin is 287 
measured and rarely is the second phase response assessed. These investigations have 288 
consistently demonstrated an higher AIR among non-diabetic Black groups (6, 7, 15, 31-33). 289 
To date only one ethnic comparison has been performed in people with T2D (the Insulin 290 
Resistance Atherosclerosis Study (IRAS); (34)), reporting significantly higher AIR amongst 291 
African-Americans compared to Whites, although not among the participants with newly 292 
diagnosed T2D, who are a nearer comparison to our participants. Notably IRAS did not assess 293 
c-peptide so it is not possible to determine beta-cell secretion, and the second phase response 294 
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was not assessed. There are other distinctions. It is well established that the phenotype of T2D 295 
in Black populations is gender specific (16, 17); higher insulin levels (16, 17), and obesity-296 
driven T2D is more common in women (16), hence our study included only men, whereas 297 
IRAS consisted of both males and females. There is a need for further studies to examine 298 
gender-specific mechanisms.  299 
Our findings of significantly lower basal c-peptide but not insulin raise concerns regarding the 300 
use of beta-cell indices based on fasting insulin, such as HOMA-B (35). These are often used 301 
to assess beta-cell function in epidemiological studies but our data suggest they may 302 
misrepresent beta-cell function in Black populations and findings of ethnic differences (16) 303 
may need to be considered with caution. 304 
When we studied beta-cell function using an oral stimulus, we recognised a significantly lower 305 
second phase c-peptide response in BAM, consistent with the hyperglycaemic clamp. However 306 
there were no differences in insulin concentrations and model derived data brought to recognise 307 
lower insulin clearance amongst BAM (Figure 4). The implication of Figure 4 is that at the 308 
same total insulin output during an intravenous or an oral challenge BAM achieve higher 309 
insulin curves, which may compensate for reduced beta-cell secretion and contribute to 310 
peripheral insulin levels. A number of previous investigations have reported reduced insulin 311 
clearance amongst non-diabetic Black populations (5-7, 13, 15, 36) and we here demonstrate 312 
that this is maintained into early T2D. The mechanisms underlying this are largely unknown, 313 
however, recent advancements in modelling techniques, that allow for hepatic versus 314 
extrahepatic clearance to be quantified, have concluded that ethnic differences in insulin 315 
clearance are solely hepatic with no extra-hepatic contribution (37).  316 
A reduction in insulin clearance is typically found following oral glucose or meal ingestion, 317 
and is characteristically of a much greater magnitude than that observed after intravenous 318 
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induction of hyperglycaemia (38-40). Reduction in insulin clearance upon increasing levels of 319 
insulin secretion is proposed to be due to the saturable nature of hepatocellular insulin receptors 320 
(41, 42). However there is also evidence that incretin hormones affect insulin clearance (39, 321 
40, 43). There has been very little study of incretin hormones and how these vary according to 322 
ethnicity. In the current study, BAM exhibited significantly higher postprandial GIP 323 
concentrations, which may have contributed to the non-significant trend for lower average 324 
insulin clearance that was observed. The effect of GIP on insulin clearance is unclear; some 325 
authors have demonstrated an insulin clearance reducing effect of GIP (44, 45), whilst others 326 
have shown no effect (42, 46). Some of the conflict in these findings may have occurred 327 
because insulin clearance appears to adapt to insulin resistance and glucose intolerance, a 328 
potential mechanism by which beta-cell function is preserved in the progression to T2D (47, 329 
48). There has been very little investigation of incretin hormones within Black populations and 330 
in those which have the focus has been on the role of incretins in the upregulation of insulin 331 
secretion; African-American children have been reported to have lower GLP-1, but similar GIP 332 
secretion compared to European-American children (49) whereas in a study of Black and White 333 
obese adolescents, Michaliszyn et al (2017) reported no difference in GLP-1 or GIP amongst 334 
Blacks (36), and Velasquez-Mieyer et al. (2003) found higher GLP-1 in obese African-335 
American adults compared with European-Americans, with no measurement of GIP (50). We 336 
modelled the impact of the mixed meal, including, but not limited to, the incretin response on 337 
insulin secretory function (‘meal effect’), but detected no ethnic differences. Michaliszyn et al 338 
(2017) modelled the ‘potentiation factor’, which describes the modulation of the relationship 339 
between glucose concentration and insulin secretion and comprises several mechanisms 340 
including the release of endogenous incretin hormones. In contrast to our data they found no 341 
differences in incretin concentrations in response to an oral glucose challenge but report a 342 
significantly higher early potentiation factor in Blacks (36). Our data suggest that by the time 343 
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diabetes develops, BAM may have no greater beta-cell response to GIP than WEM, but that 344 
their higher GIP response may concur to cause lower average insulin clearance in response to 345 
hyperglycaemia, which results in maintenance of peripheral insulin concentrations, and that 346 
these mechanisms provide some compensation for the significantly lower insulin secretory 347 
capacity of the beta-cells.  348 
The strengths and limitations of our work warrant discussion. We have not investigated the 349 
cellular mechanisms that underlie the differences in metabolic function between BAM and 350 
WEM. Additionally we have only captured the metabolic phenotype of T2D, and of men, 351 
therefore we cannot allude to the mechanisms by which hyperglycaemia progresses and how 352 
this may be distinct among BAM, and our findings may not extrapolate to women. Our study 353 
has explored ethnic differences in insulin secretory function and in doing so has a-priori 354 
assessed a comprehensive portfolio of measures that attempt to thoroughly characterise insulin 355 
secretory function. Although we have conducted a large number of comparisons we have not 356 
corrected for multiple testing because our outcome variables are not independent of one another 357 
and the differences are very large and highly significant, therefore we are confident that the 358 
differences we have observed are likely to represent real differences. Finally, our model aided 359 
computation of the meal effect on beta cell function (see Supplementary Material) has not been 360 
validated with ad hoc experiments.  361 
Major strengths of our work are our use of intensive, sophisticated techniques, and our well-362 
matched participant groups; our ethnic groups had the same duration of diagnosed diabetes, 363 
HbA1c, fasting glucose and clinical management, and exhibited almost identical glucose 364 
responses to a meal challenge. We are therefore confident we have recognised novel ethnic 365 
distinctions in T2D pathophysiology which may have important clinical implications. The 366 
intensive nature of our protocol precludes a much larger study, and may have missed additional 367 
more subtle ethnic differences, but the value of our approach is perhaps best seen in the way 368 
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our data have been able to extend the conclusions of epidemiological studies such as IRAS, 369 
discussed above. Our data suggest that loss of beta-cell insulin secretory function occurs earlier 370 
in the development of T2D in BAM compared to WEM, however the mechanisms that drive 371 
beta-cell dysfunction in BAM are not clear. Potentially BAM may have lower beta-cell mass 372 
or a steeper slope of decline in beta-cell function as T2D develops.  373 
In conclusion we have recognised in this study that deficits in beta-cell function may effect 374 
hyperglycaemia in BAM more strongly than WEM. Further studies are needed to ascertain 375 
whether the incretin hormones play a damage-limitation role in maintaining peripheral insulin 376 
concentrations by reducing insulin clearance in BAM. Meanwhile, it may be pertinent to 377 
consider therapeutic strategies that augment these physiological processes; BAM may achieve 378 
greater clinical benefit from therapeutic agents that support beta-cell function such as the 379 
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Table 1.  Clinical characteristics of Black African and White European participants  418 
 BAM (n = 19) WEM (n = 15)  Mean difference (95% CI) p-value 
Age (years) 54.1 (7.7) 55.5 (7.1) -1.3 (-6.6 to 3.9) 0.602 
Weight (kg) 90.6 (9.2) 94.2 (11.6) -3.6 (-10.8 to 3.7) 0.326 
Height (cm) 175.4 (7.4) 176.8 (5.8) -1.4 (-6.1 to 3.4) 0.561 
BMI (kg/m2) 29.5 (2.6) 30.1 (2.7) -0.62 (-2.5 to 1.3) 0.510 
Waist circumference (cm) 103.7 (8.2) 107.5 (8.8) -3.86 (-9.8 to 2.1) 0.194 
Visceral fat area (cm2)† 130.8 (54.1) 189.0 (75.7) -58.2 (-104.2 to -12.2) 0.015 
Thigh skeletal muscle area (cm2)† 434.2 (49.6) 379.2 (57.2) 55.0 (17.0 to 93.0) 0.006 
Duration of diabetes (years) 2.8 (1.2) 2.9 (1.0) -0.09 (-0.88 to 0.69) 0.815 
Fasting glucose (mmol/l) 6.67 (0.97) 6.81 (1.37) -0.14 (-0.95 to 0.68) 0.732 
HbA1c (%) 6.7 (0.68) 6.6 (0.72) 0.11 (-0.38 to 0.60) 0.650 
HbA1c (mmol/mol) 49.9 (7.7) 48.6 (7.8) 1.26 (-4.15 to 6.74) 0.631 
Systolic blood pressure (mm Hg) 137.3 (14.1) 131.8 (13.9) 5.5 (-3.3 to 15.4) 0.262 
Diastolic blood pressure (mm Hg) 85.6 (7.4) 82.9 (10.1) 2.7 (-3.4 to 8.8) 0.376 
Total cholesterol (mmol/l) 4.12 (0.70) 4.30 (0.72) -0.18 (-0.68 to 0.32) 0.470 
LDL-cholesterol (mmol/l) 2.34 (0.53) 2.29 (0.70) 0.06 (-0.37 to 0.48) 0.794 
HDL-cholesterol (mmol/l) 1.17 (0.38) 1.24 (0.24) -0.07 (-0.29 to 0.16) 0.557 
Triacylglycerol (mmol/l) 1.32 (0.75) 1.70 (0.71) -0.38 (-0.89 to 0.14) 0.143 
Metformin use (%) 74 53  0.09 
Data are arithmetic mean (standard deviation). Differences between ethnic groups tested using independent 419 
samples t-test. †data obtained for 14 WEM and 19 BAM. BMI, body mass index; HbA1c, glycated haemoglobin; 420 




Table 2.  Hyperglycaemic clamp assessment of insulin secretory function in Black African and White European participants  
 BAM (n = 19) WEM (n = 15) Mean difference/Ratio of 
geometric mean (95% CI) 
p-value 
Fasting glucose (mmol/l) 7.39 (1.59) 7.20 (1.12) 0.19 (-0.80 to 1.18) 0.699 
Fasting insulin (pmol/l)# 66.6 (50.8 to 87.4) 84.0 (57.3 to 123.3) 0.81 (0.51 to 1.23) 0.290 
Insulin iAUC 0-10 mins (pmol/l min-1)# 103.8 (28.5 to 378.1) 75.0 (13.8 to 408.5) 0.77 (0.13 to 4.48) 0.764 
Insulin iAUC 10-120 mins (pmol/l min-1)# 14454 (8430 to 24786) 21999 (13636 to 35498) 0.57 (0.32 to 1.02) 0.060 
Fasting c-peptide (nmol/l) 0.576 (0.193) 0.837 (0.299) -0.261 (-0.433 to -0.089) 0.004 
C-peptide iAUC 0-10 mins (nmol/l min-1)# 0.697 (0.131 to 1.546) 1.227 (0.273 to 2.897) 0.98 (0.20 to 4.86) 0.984 
C-peptide iAUC 10-120 mins (nmol/l min-1)# 70.6 (52.5 to 94.8) 115.1 (84.8 o 156.3) 0.55 (0.37 to 0.83) 0.006 
1 [(pmol/m2 BSA)/(mmol/l min-1)]# 65.6 (27.0 to 159.2) 95.3 (42.5 to 213.8) 0.69 (0.21 to 2.20) 0.507 
2 [(pmol min-1 m2 BSA)/mmol/l)]# 6.8 (4.1 to 11.4) 12.4 (7.2 to 21.6) 0.55 (0.26 to 1.14) 0.105 
M value (mg/m2 BSA min-1) 167.2 (38.4) 185.4 (37.0) -18.2 (-44.7 to 8.4) 0.173 
Average insulin clearance (mL/m2 BSA min-1)# 897.6 (699.0 to 1152.4) 830.8 (637.2 to 1082.9) 1.08 (0.76 to 1.55) 0.663 
Data are mean (SD) or geometric mean (95% CI) for log-normal data#. Positively skewed data were transformed (log10) prior to statistical testing. Differences between ethnic 
groups tested using independent samples t-test. 1, glucose sensitivity of  cell during first-phase insulin secretion; 2, glucose sensitivity of  cell during second-phase insulin 
secretion; BSA, body surface area; iAUC, incremental area under the curve, calculated using the trapezoidal rule; M, glucose disposal in final 60 minutes of the clamp; SI, 
insulin sensitivity. iAUC 0 – 10 mins represents first phase, iAUC 10 – 120 mins represents second phase.
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Table 3.  Meal tolerance test assessment of insulin secretory function in Black African and White European participants  
 BAM (n = 18) WEM (n = 15) Mean difference/Ratio of 
geometric mean (95% CI) 
p-value 
Fasting glucose (mmol/l) 7.34 (1.35) 7.28 (1.34) 0.10 (-0.86 to 1.06) 0.839 
Glucose iAUC (mmol/l min-1)# 378.4 (250.1 to 572.3) 476.2 (377.7 to 600.5) 0.86 (0.57 to 1.29) 0.459 
Fasting insulin (pmol/l)# 85.1 (67.6 to 107.2) 102.3 (74.1 to 141.3) 0.82 (0.57 to 1.19) 0.284 
Insulin iAUC (nmol/l min-1)# 47.4 (32.6 to 68.8) 59.4 (42.3 to 84.8) 0.89 (0.59 to 1.35) 0.566 
Fasting c-peptide (nmol/l) 0.603 (0.216 0.881 (0.340) -0.278 (-0.477 to -0.080) 0.008 
c-peptide iAUC (nmol/l min-1) 65.4 (17.7) 88.5 (29.4) -23.2 (-40.0 to -6.3) 0.009 
Fasting GLP-1 (pmol/l) 12.1 (8.6) 11.7 (6.7) 0.48 (-5.07 to 6.03) 0.861 
GLP-1 iAUC (pmol/l min-1)# 810.2 (519.2 to 1264.7) 861.0 (536.2 to 1382.6) 0.95 (0.57 to 1.57) 0.832 
Fasting GIP (ng/l) 44.6 (25.3) 31.8 (13.8) 12.8 (-2.10 to 27.7) 0.089 
GIP iAUC (µg/l min-1) 46.8 (17.4) 33.9 (12.0) 12.9 (2.1 to 23.7) 0.021 
Fasting NEFA (µmol/l) 600.0 (186.4) 631.0 (192.4) -31.0 (-165.9 to 103.9) 0.643 
NEFA iAUC (µmol/l min-1) -52576 (26325) -61337 (26442) 8760 (-10047 to 27568) 0.349 
1 [(pmol/m2 BSA)/(mmol/l min-1)] 1420.1 (1184.2) 1134.6 (710.7) 285.5 (-447.2 to 1018.2) 0.432 
Average insulin clearance (mL/m2 BSA min-1) 506.2 (194.2) 630.1 (218.6) -123.9 (-270.5 to 22.6 ) 0.095 
Meal effect (%) 51.0 (12.9) 49.5 (6.4) 1.5 (-6.2 to 9.1) 0.700 
Data are mean (SD) or geometric mean (95% CI) for log-normal data#. Positively skewed data transformed (log10) prior to statistical testing. Differences between ethnic 
groups tested using independent samples t-test. 1, glucose sensitivity of  cell during first-phase insulin secretion; iAUC, incremental area under the curve, calculated using 





Figure 1. Serum insulin (A) and c-peptide (B) responses in the hyperglycaemic clamp in BAM 3 
and WEM 4 















Figure 2. Plasma glucose (A), serum insulin (B), c-peptide (C), and non-esterified fatty acid 20 








Figure 3. Insulin secretion rates at 5 increasing plasma glucose concentrations during the meal 24 





Figure 4. Relationship between average insulin clearance and average insulin concentration 30 
during the hyperglycemic clamp and the mixed meal test in BAM and WEM. Average insulin 31 
clearance (ml.min-1.m-2 BSA): BAM = 224 + (109151/average insulin concentration), WEM = 32 
425 + (109151/average insulin concentration). 33 
 34 
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Supplementary material 181 
 182 
Derivation of the formula to compute insulin clearance 183 
 184 
The derivation of the formula to compute insulin clearance starts from the general formula: 185 





Over the 180 minutes of the mixed meal tolerance test or the 120 minutes of the hyperglycemic clamp, 188 
the clearance can be computed as a ratio of the total areas under the curves of insulin outflux rate and 189 
insulin concentration: 190 




However, total insulin outflux equals total insulin secretion rate minus the amount of insulin secreted 192 
and not yet irreversibly lost. Then: 193 
𝐴𝑈𝐶𝑂𝑢𝑡𝑓𝑙𝑢𝑥 =  𝐴𝑈𝐶𝐼𝑆𝑅 − (𝐼𝐹𝑖𝑛𝑎𝑙 − 𝐼𝐵𝑎𝑠𝑎𝑙) ∙ 𝐷𝑉𝐼𝑛𝑠 194 
in which 𝐼𝐹𝑖𝑛𝑎𝑙is insulin concentration at the end of the study, 𝐼𝐵𝑎𝑠𝑎𝑙 is insulin concentration at the 195 
beginning of the study and 𝐷𝑉𝐼𝑛𝑠 is the volume of distribution of insulin. 196 
Since: 197 
𝐷𝑉 = 𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 ∙ 𝑀𝑅𝑇 198 
in which MRT is the mean residence time of insulin, it follows:  199 
 200 
𝐴𝑈𝐶𝐼 ∙  𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒𝐼𝑛𝑠 = 𝐴𝑈𝐶𝐼𝑆𝑅 − (𝐼𝐹𝑖𝑛𝑎𝑙 − 𝐼𝐵𝑎𝑠𝑎𝑙) ∙ 𝑀𝑅𝑇𝐼𝑛𝑠  ∙ 𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒𝐼𝑛𝑠 201 
 202 
The final formula becomes: 203 
𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒𝐼𝑛𝑠 =  
𝐴𝑈𝐶𝐼𝑆𝑅





As to the value used for 𝑀𝑅𝑇𝐼𝑛𝑠 in the present paper, we used the values reported by Navalesi R et al. 206 
(1978) J Clin Invest;61(1):197-208; in that paper, the average MRT in people with type 2 diabetes 207 
was ≈27 min, whereas it was ≈18 min in healthy controls.  208 
This formula assumes that at the final time point a new steady state is achieved, i.e. that the plasma 209 
compartment is in equilibrium with all the other compartments in which insulin distributes. In the 210 
present paper, the almost flat insulin concentration during the last 30 min of the hyperglycemic clamp 211 
shows that the above assumption was fulfilled. As to the mixed meal test, a nonsteady state, hallmarked 212 
by steadily decreasing insulin concentrations, was still present at the end of the test. However, since the 213 
final value of insulin was very close to the basal concentration, the product (𝐼𝐹𝑖𝑛𝑎𝑙 − 𝐼𝐵𝑎𝑠𝑎𝑙) ∙ 𝑀𝑅𝑇𝐼𝑛𝑠 214 
and its potential error were small numbers, which minimally affected the computation of average 215 
clearance. 216 
Finally, this formula computes the average insulin clearance over a time interval during which insulin 217 
concentration achieves a measured average value (these are the numbers plotted in fig. 4 of the main 218 
text), not the insulin clearance at a determined insulin concentration. 219 
 220 
Computation of the “meal effect” on the beta cell response to glucose 221 
Computation of the ‘meal effect’ took advantage of the two reconstructions of beta cell function 222 
carried out in each subject, one after intravenous glucose administration (hyperglycemic clamp), the 223 
other after oral administration in the mixed meal tolerance test. We report an index case (SDGS003) 224 
for the sake of clarity. 225 
The plasma glucose curve of the meal test of SDGS003is shown in Figure S1. Data modelling generated 226 
a mathematical reconstruction of the beta cell response to glucose during a mixed meal test which fitted 227 
the C-peptide experimental points as shown in Figure S2 with the corresponding insulin secretion rate 228 
shown in Figure S3. 229 
The plasma glucose curve of the hyperglycemic clamp of SDGS003 is shown in Figure S4. Data 230 
modeling generated a mathematical reconstruction of the beta cell response to glucose during 231 
intravenous glucose administration which fitted the C-peptide experimental points as shown in Figure 232 
S5 with the corresponding insulin secretion rate shown in Figure S6. 233 
At this point, the mathematical reconstruction of the beta cell response to glucose of SDGS003 during 234 
intravenous glucose administration was “fed” with the plasma glucose concentration of Figure S1, i.e. 235 
the glucose curve of the meal test, and generated the insulin secretory response of Figure S7. The meal 236 




𝑀𝑒𝑎𝑙 𝑒𝑓𝑓𝑒𝑐𝑡 =  




in which 𝐴𝑈𝐶 𝐼𝑆𝑅𝑀𝑒𝑎𝑙 is the area under the curve of Figure S3 and 𝐴𝑈𝐶 𝐼𝑆𝑅𝐼𝑛𝑡𝑟𝑎𝑣𝑒𝑛𝑜𝑢𝑠 is the area 241 
under the curve of Figure S7. Both areas were computed by the SAAM II 1.2 modeling software. 242 
 243 
Nonlinear regression analysis of the relationship between insulin clearance and insulin 244 
concentration 245 
Figure S8 shows the plot of mean insulin concentration during either the hyperglycemic clamp or the 246 
meal tolerance test (x axis) and average insulin clearance (y axis). The relationship is strongly nonlinear 247 
and apparently hyperbolic, as confirmed by regression analysis (linear regression: R2 0.338; hyperbolic 248 
relationship: R2 0.834; p<0.01); in agreement with existing evidence (Cobelli C. & Pacini G. (1988) 249 
Diabetes; 37(2):223-31. Van Cauter E et al. (1992) Diabetes; 41(3):368-77), we did not find this to be 250 
the case when we investigated the relationship between c-peptide concentration and c-peptide clearance, 251 
no inverse relationship was evident (p>0.05; Figure S9). For the insulin data the best fitting hyperbola 252 
was found by identifying the unknown parameters b1 and b2 of the following equation: 253 
y = b1 + (b2/x) 254 
We then tested the hypothesis that the hyperbola describing the relationship average insulin 255 
clearance/concentration may not be the one and the same in WEM and BAM. To do so, we repeated 256 
the nonlinear regression analysis with the following equation: 257 
y = (b1+b3*Ethnicity)+[(b2+b4*Ethnicity)/x] 258 
in which Ethnicity takes the value 0 or 1 if the individual is WEM or BAM, respectively. If the same 259 
hyperbola can describe WEM and BAM together, b3 and b4 will not be statistically different from 0. 260 
The unknown parameter b3, but not b4, turned out to be statistically different from 0. Thus, two different 261 
hyperbolas (fig 4 of the main paper) are needed to best describe the relationship between average insulin 262 
clearance and average insulin concentration in WEM and BAM. 263 
 264 






Fig. S1. Plasma glucose experimental points (filled circles) and input function (dotted line) of the 269 
mathematical model of beta cell function during the MMTT in the index case SDGS003 270 
 271 
 272 
Fig. S2. Plasma C-peptide experimental points (filled circles) and model fit (dotted line) to the data of 273 



















































Fig. S3. Insulin secretion rate (dotted line) during the MMTT in the index case SDGS003 as 276 
computed by the mathematical model. 277 
 278 
 279 
Fig. S4. Plasma glucose experimental points (filled circles) and input function (dotted line) of the 280 
mathematical model of beta cell function during the hyperglycemic clamp in the index case SDGS003 281 
 282 




Fig. S5. Plasma C-peptide experimental points (filled circles) and model fit (dotted line) to the data of 285 
the MMTT in the index case SDGS003. 286 
 287 
 288 
Fig. S6. Insulin secretion rate (dotted line) during the hyperglycemic clamp in the index case 289 
SDGS003 as computed by the mathematical model. 290 
 291 











































Fig. S7. Insulin secretion rate (dotted line) computed by the model of beta cell function reconstructed 294 
during the hyperglycemic clamp, when the plasma glucose input function is the one of the MMTT 295 
(fig. S2), not the one of the hyperglycemic clamp (fig. S5), in the index case SDGS003. 296 
Fig S8. 297 
Average insulin concentration (pmol.l-1, x axis) and average insulin clearance (pmol.min-1.m-2 BSA, y 298 







Fig S9. Average c-peptide concentration (nmol.l-1, x axis) and average c-peptide clearance (ml.min-304 
1.m-2 BSA, y axis) in all the tests (meal tolerance test and hyperglycemic clamps) reported in the 305 
present paper. 306 
 307 
 308 
 309 
